Date: Wednesday, May 17, 2017
Time: 10:00 AM – 12:00 PM
Location: Foege N-130A

Members Present:
1. Thea Brabb, Comparative Medicine (Animal Containment Expert)
2. Lesley Colby, Comparative Medicine (Animal Containment Expert)
3. Richard Grant, Washington National Primate Research Center
4. Garry Hamilton (Community Member)
5. Kevin Hybiske, Allergy and Infectious Diseases
6. Stephen Libby, Laboratory Medicine (IBC Chair)
7. Scott Meschke, Environmental & Occupational Health Sciences
8. David Scarsella, Pacific Northwest Diabetes Research Institute (Community Member)
9. Jason Smith, Microbiology (IBC Vice Chair)
10. Eric Stefansson, Environmental Health & Safety (Biosafety Officer, Animal Containment Expert)
11. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 am. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the April 19, 2017 meeting.
   - A member made a motion to approve the April 19, 2017 minutes. Another member seconded the motion.
   - The committee voted unanimously, with two abstentions, to approve the April 19, 2017 meeting minutes.

4. **OLD BUSINESS**
   - At the February IBC meeting, Dr. Phillip’s BUA was approved pending biosafety officer review of the IACUC protocol submission. The IACUC protocol was submitted and the BUA letter was sent out.
   - At the March IBC meeting, Dr. Grant’s BUA was approved pending a final lab inspection and finalized SOPs. The finalized SOPs are still pending.
   - At the April IBC meeting, Dr. Cui’s BUA was approved pending clarification of the rooms that will be used. Dr. Cui clarified that the rooms listed on the BUA letter were correct and the letter was sent out.
   - At the April IBC meeting, Dr. Fuller’s BUA was approved pending biosafety officer review of the IACUC protocol & discussing animal housing room assignments with Comparative Medicine. The IACUC protocol has not yet been submitted.
   - At the April IBC meeting, Dr. Garden’s BUA was approved pending completion of the PI’s biosafety training. The training was completed and the BUA letter was sent out.
   - At the April meeting, Dr. Hybiske’s BUA was approved pending receipt of NIH approval for Chlamydia strains falling under section III-A of the NIH guidelines. The NIH approval is still pending.
   - At the April meeting, Dr. Murphy’s BUA letter was approved pending biosafety officer review of the IACUC protocol and pending a decision from the Employee Health Physician regarding whether the yellow fever vaccine should be offered to researchers working on this project. The IACUC protocol has not yet been submitted. The researchers will be required to meet with an Employee Health medical provider and be offered the yellow fever vaccine before working on this project.
   - At the April meeting, Dr. Palmiter’s BUA was approved pending submission of an updated bloodborne pathogens exposure control plan. This was completed and the BUA letter was sent out.
   - At the April IBC meeting, Dr. West’s BUA was approved pending the rooms on the BUA and IACUC protocol matching up. The rooms match up and the BUA letter was sent out.

5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the NIH Guidelines, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
   
   a. Biosafety Officer Report
• Dr. Nemhauser and Dr. Imaizumi each renewed a BUA involving transgenic plants.
• Dr. Marra renewed a BUA involving Treponema pallidum administered to rabbits.
• Dr. Landis renewed a BUA involving human blood, tissue, and body fluids.
• Dr. Bremner renewed a BUA involving human blood and body fluids.
• Dr. Roberts renewed a BUA involving various non-recombinant risk group 1 and 2 bacteria.
• Dr. DeForest renewed a BUA involving non-pathogenic strains of E. coli.
• Dr. Guttman received a new BUA for non-pathogenic strains of E. coli.
• Dr. Wang renewed a BUA involving human blood samples and human eye tissue samples.
• Dr. Hackett renewed a BUA involving P. gingivalis.
• The IBC Chair sought a motion to approve this month’s Biosafety Officer Report.
• A member made a motion to approve this month’s Biosafety Officer Report.
  Another member seconded the motion.
• The Committee unanimously voted to approve this month’s Biosafety Officer Report.

6. INDIVIDUAL PROJECT REVIEWS

1. Adams-Waldorf, Kristina, change, Experimental Model for Chorioamnionitis and Preterm Labor
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • A discussion was raised about the strains of Group B streptococcus that will be used. One is a clinical isolate and the other is an isogenic mutant of the same clinical isolate lacking the hyaluronidase gene. The mutant was created using recombinant DNA technology. The strains will be used in a non-human primate model.
   • The draft BUA letter was shown.
   • The lab has recently been inspected and did not need to be re-inspected for this change. All of the required trainings have been completed.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Adams-Waldorf.
   • The Committee voted unanimously to approve the draft BUA for Dr. Adams-Waldorf.

2. Byers, Peter, renewal, Collagen Diagnostic Laboratory and Research Repository for Heritable Disorders of Bone, Blood Vessels and Skin
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • The investigator studies genes involved in connective tissue disorders.
   • Human induced pluripotent stem cells (iPS cells) are created using Sendai viral vectors.
   • A discussion occurred about the BUA letter. The correct nomenclature would be Sendai viral vectors rather than Sendai virus. The biosafety officer will make the correction.
   • The lab has been inspected and no deficiencies were found. The required trainings have been completed.
   • The draft BUA letter was shown.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Byers.
   • The Committee voted unanimously to approve the draft BUA for Dr. Byers.
3. Corey, Eva, renewal, Pre-Clinical Models, Mechanisms, and Markers of Prostate Cancer and Prostate Cancer Metastasis
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - This is a renewal. The goal of the research is to uncover mechanisms underlying advanced prostate cancer and to test potential treatments.
   - Human cells transfected with recombinant DNA are used on the project.
   - The lab has been inspected and no deficiencies were found. The required trainings have been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Corey.
   - The Committee voted unanimously to approve the draft BUA for Dr. Corey.

4. Frevert, Charles, renewal, Use of BSL2 agents in Histology and Imaging Core
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - This is a renewal for the use of cells in the Histology and Imaging Core at South Lake Union.
   - BSL-1 or BSL-2 cells can be used at this facility. Each user will have their own BUA approval for the cells they will use in the Histology and Imaging Core.
   - The lab has been inspected and no deficiencies were found. The required trainings have been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Frevert.
   - The Committee voted unanimously, with one abstention, to approve the draft BUA for Dr. Frevert.

5. Gallagher, Evan, renewal, Molecular and Biochemical Effects of Pollutants in Fish and Human Cells
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The goal of the project renewal is to study how ocean acidification and environmental chemicals affect olfactory function in salmon and to compare and model the ability of industrial compounds to produce oxidative stress in zebrafish.
   - Transgenic zebrafish are used on the project.
   - The draft BUA letter was shown.
   - The lab has been inspected and no deficiencies were found. The required trainings have been completed.
   - The IACUC renewal has not yet been submitted. The approval will be issued pending the biosafety officer’s review of the IACUC protocol.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Gallagher.
   - The Committee voted unanimously to approve the draft BUA for Dr. Gallagher, pending completion of the IACUC protocol.

6. Hampe, Christiane, renewal, Autoantibodies and Anti-idiotypic Antibodies in Type 1 Diabetes
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The draft BUA letter was shown.
   - The overall goal of the research is to investigate the immunological pathways leading to the development of autoimmune diabetes.
• Adeno-associated viral vectors are used on the project in a mouse model.
• The IACUC renewal has not yet been submitted. The approval will be issued pending the biosafety officer’s review of the IACUC protocol.
• The lab has been inspected and all deficiencies were corrected. The required trainings have been completed.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hampe.
• The Committee voted unanimously to approve the draft BUA for Dr. Hampe, pending completion of the IACUC protocol.

7. Hu, Shiu-Lok, renewal, HIVRAD: Core B: Virology/Immunology
• The assigned IBC Primary Reviewer presented the Primary Review.
• The overall objective of the research is to improve the pigtail macaque HIV/AIDS model so that it is more representative of human HIV infections and human AIDS.
• Primate lentiviruses, including simian-human immunodeficiency virus (SHIV), are used. Plasmid DNA is also used.
• The draft BUA letter was shown.
• The lab has been inspected and no deficiencies were found. The required trainings have been completed.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hu.
• The Committee voted unanimously to approve the draft BUA for Dr. Hu.

8. Hyde, Jennifer, change, Contribution of virus-host interactions to viral pathogenesis
• The assigned IBC Primary Reviewer presented the Primary Review.
• This is a change request. The investigator would like to add lentiviral vectors that express oncogenic inserts. The lentiviral vectors are second generation. BSL-2 with BSL-3 practices will be used.
• The draft BUA letter was shown.
• The lab has been inspected and no deficiencies were found. The required trainings have been completed.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hyde.
• The Committee voted unanimously to approve the draft BUA for Dr. Hyde.

9. Pasupathy, Anitha, new, Neural basis of visual shape representation and recognition
• The assigned IBC Primary Reviewer presented the Primary Review.
• This is a new application from an established investigator. The lab studies the neural basis for visual shape recognition.
• AAV expressing GFP (green fluorescent protein) will be administered to macaques.
• A herpes B exposure kit will be available to personnel on the project who are working with macaques.
• The draft BUA letter was shown.
• The lab has been inspected and no deficiencies were found. The required trainings have been completed.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Pasupathy.
• The Committee voted unanimously to approve the draft BUA for Dr. Pasupathy.

10. Scott, John, renewal, AKAP structure and Function
• The assigned IBC Primary Reviewer presented the Primary Review.
• Several types of viral vectors are used on the project, including adenoviral vectors, lentiviral vectors, gammaretroviral vectors, and adeno-associated viral vectors.
• The draft BUA letter was shown.
• The lab has been inspected and no deficiencies were found. The required trainings have been completed.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Scott.
• The Committee voted unanimously to approve the draft BUA for Dr. Scott.

11. Servetnick, Marc, new, *Roles of vertebrate 'mesoderm genes' in development of the sea anemone Nematostella vectensis*
• The assigned IBC Primary Reviewer presented the Primary Review.
• This is a new project designed to study the roles of specific genes in the development of sea anemone embryos.
• Transgenic sea anemones (*Nematostella vectensis*) will be used. The embryos are not likely to survive to adulthood. Regardless, the lab has precautions in place to ensure that embryos cannot leave the laboratory. Drain covers and seals are in place.
• The draft BUA letter was shown.
• The lab has been inspected and no deficiencies were found. The required trainings have been completed.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Servetnick.
• The Committee voted unanimously to approve the draft BUA for Dr. Servetnick.

SUBCOMMITTEE REPORTS:

12. Shah, Javeed, new, *Immunology and Genetics of Infectious Diseases and Vaccines*
• Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
• This is a new BUA from an investigator previously working in Dr. Thomas Hawn’s lab. The Hawn IACUC protocol is being transferred to Dr. Shah.
• A medical management plan is in place for *Mycobacterium tuberculosis*. Researchers working on this project will have skin tests every six months.
• The draft BUA letter was shown.
• The lab has been inspected and no deficiencies were found. The required trainings have been completed.
• A member made a motion to approve the draft BUA letter for Dr. Shah. Another member seconded the motion.
• The Committee voted unanimously to approve the draft BUA for Dr. Shah.

OTHER VOTING ITEMS

13. 2017 BUA application revisions
• The IBC coordinator presented the revisions that will be made to the 2017 BUA applications. The revisions are mostly minor. The most significant change is that clinical trial PIs will now fill out a separate application with questions specific to human gene transfer research.
• The committee members had some recommendations for edits, which will be incorporated.
The Committee voted unanimously to approve the revisions to the 2017 BUA application.

14. Serum Banking Policy Update

- The UW Serum Banking Policy has been developed for research involving biohazardous agents. It was developed by EH&S Employee Health and EH&S Research and Occupational Safety.
- For work with most biological agents, serum banking is neither required nor offered.
- For work with some biological agents (e.g., Coxiella burnetti), the UW must offer serum banking, but employees are not required to participate in order to work with those agents.
- For work with a select few biological agents (e.g., highly pathogenic avian influenza), serum banking is required for all employees (research and support staff) who work with or may be exposed to those biological agents per the CDC’s requirements. University employees may not work in areas where these agents are in use unless they participate in serum banking.
- The serum banking policy also includes provisions about how serum is collected, stored, and used.
- The serum banking policy will be added to the UW Biosafety Manual and it has been reviewed by the assistant attorney general.
- The Committee voted unanimously to approve the Serum Banking Policy.

ISSUES FROM THE FLOOR & PUBLIC COMMENTS:
There were no issues from the floor, and no public comments.

MEETING ADJOURNED AT APPROXIMATELY 12:06 p.m.